Correlation of crispr efficacy to functional outcomes in duchenne muscular dystrophy

This $420,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Myogene Bio LLC, a woman-owned small biotechnology company, to evaluate the efficacy of CRISPR gene editing technology in treating Duchenne muscular dystrophy (DMD). The research aims to correlate CRISPR efficacy with functional outcomes in preclinical DMD models, building on the company's previous federal grant awards focused on developing gene editing therapies for this rare genetic disorder. The 2-year project, running from August 2024 to July 2026, involves sophisticated molecular techniques to assess dystrophin expression, vector delivery strategies, and functional improvements in humanized mouse models. This federal grant award represents Myogene Bio's continued efforts to advance innovative therapeutic approaches for addressing genetic muscular conditions through cutting-edge gene editing technologies.